Cryopreservation of rat hepatocytes with disaccharides for cell therapy

Cryopreservation of hepatocytes is a crucial step in the implementation of cell therapy for treating certain liver diseases. In the present study we investigated the effect of the some disaccharides on the cryopreservation of rat hepatocytes. Liver cells were frozen in media in the presence or absen...

Full description

Saved in:
Bibliographic Details
Published in:Cryobiology 2017-10, Vol.78, p.15-21
Main Authors: Cardoso, Liana Monteiro da Fonseca, Pinto, Marcelo Alves, Henriques Pons, Andrea, Alves, Luiz Anastácio
Format: Article
Language:English
Subjects:
Animals
Cell Survival - drug effects
Cell therapy
Cell- and Tissue-Based Therapy
Cells, Cultured
Cryopreservation
Cryopreservation - methods
Cryoprotective Agents - pharmacology
Dimethyl Sulfoxide - pharmacology
Disaccharides
Disaccharides - pharmacology
Freezing
Glucose - pharmacology
Hepatocyte
Hepatocytes - drug effects
Humans
Male
Rats
Rats, Wistar
Sucrose - pharmacology
Thehalose
Trehalose - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cryopreservation of hepatocytes is a crucial step in the implementation of cell therapy for treating certain liver diseases. In the present study we investigated the effect of the some disaccharides on the cryopreservation of rat hepatocytes. Liver cells were frozen in media in the presence or absence of low concentrations of Me2SO (5% Me2SO) supplemented with varying concentrations of disaccharides (sucrose, glucose and trehalose). After 7 days of cryopreservation, the hepatocytes were thawed and viability was measure by exclusion of trypan blue and by the MTT technique, as well as by determining albumin production. Among the investigated disaccharides and concentrations, 0.2 M trehalose showed the best overall outcome. Compared to the use of Me2SO alone, significant improvement in post-thaw cell viability was observed. The new solution may reduce Me2SO side effects on patients and improve the viability and quality of cryopreserved hepatocytes.
ISSN:0011-2240
1090-2392
DOI:10.1016/j.cryobiol.2017.07.010